Advertisement

Development of a biomarker panel to predict cardiac resynchronization therapy response: Results from the SMART-AV trial

Published:November 23, 2018DOI:https://doi.org/10.1016/j.hrthm.2018.11.026

      Background

      Predicting a favorable cardiac resynchronization therapy (CRT) response holds great clinical importance.

      Objective

      The purpose of this study was to examine proteins from broad biological pathways and develop a prediction tool for response to CRT.

      Methods

      Plasma was collected from patients before CRT (SMART-AV [SmartDelay Determined AV Optimization: A Comparison to Other AV Delay Methods Used in Cardiac Resynchronization Therapy] trial). A CRT response was prespecified as a ≥15-mL reduction in left ventricular end-systolic volume at 6 months, which resulted in a binary CRT response (responders 52%, nonresponders 48%; n = 758).

      Results

      Candidate proteins (n = 74) were evaluated from the inflammatory, signaling, and structural domains, which yielded 12 candidate biomarkers, but only a subset of these demonstrated predictive value for CRT response: soluble suppressor of tumorgenicity-2, soluble tumor necrosis factor receptor-II, matrix metalloproteinase-2, and C-reactive protein. These biomarkers were used in a composite categorical scoring algorithm (Biomarker CRT Score), which identified patients with a high/low probability of a response to CRT (P <.001) when adjusted for a number of clinical covariates. For example, a Biomarker CRT Score of 0 yielded 5 times higher odds of a response to CRT compared to a Biomarker CRT Score of 4 (P <.001). The Biomarker CRT Score demonstrated additive predictive value when considered against a composite of clinical variables.

      Conclusion

      These unique findings demonstrate that developing a biomarker panel for predicting individual response to CRT is feasible and holds potential for point-of-care testing and integration into evaluation algorithms for patients presenting for CRT.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Heart Rhythm
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bristow M.R.
        • Saxon L.A.
        • Boehmer J.
        • et al.
        Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
        N Engl J Med. 2004; 350: 2140-2150
        • Cleland J.G.
        • Daubert J.C.
        • Erdmann E.
        • Freemantle N.
        • Gras D.
        • Kappenberger L.
        • Tavazzi L.
        • Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators
        The effect of cardiac resynchronization on morbidity and mortality in heart failure.
        N Engl J Med. 2005; 352: 1539-1549
        • Yancy C.W.
        • Jessup M.
        • Bozkurt B.
        • et al.
        2017 ACC/AHA/HFSA Focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.
        J Card Fail. 2017; 23: 628-651
        • Boriani G.
        • Gasparini M.
        • Landolina M.
        • et al.
        Effectiveness of cardiac resynchronization therapy in heart failure patients with valvular heart disease: comparison with patients affected by ischaemic heart disease or dilated cardiomyopathy. The InSync/InSync ICD Italian Registry.
        Eur Heart J. 2009; 30: 2275-2283
        • Goldenberg I.
        • Moss A.J.
        • Hall W.J.
        • et al.
        Predictors of response to cardiac resynchronization therapy in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT).
        Circulation. 2011; 124: 1527-1536
        • Pires L.A.
        • Abraham W.T.
        • Young J.B.
        • Johnson K.M.
        • MIRACLE and MIRACLE-ICD Investigators
        Clinical predictors and timing of New York Heart Association class improvement with cardiac resynchronization therapy in patients with advanced chronic heart failure: results from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) and Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE-ICD) trials.
        Am Heart J. 2006; 151: 837-843
        • Ellenbogen K.A.
        • Gold M.R.
        • Meyer T.E.
        • et al.
        Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in cardiac resynchronization therapy (SMART-AV) trial: a randomized trial comparing empirical, echocardiography-guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy.
        Circulation. 2010; 122: 2660-2668
        • Berger R.
        • Shankar A.
        • Fruhwald F.
        • Fahrleitner-Pammer A.
        • Freemantle N.
        • Tavazzi L.
        • Cleland J.G.
        • Pacher R.
        Relationships between cardiac resynchronization therapy and N-terminal pro-brain natriuretic peptide in patients with heart failure and markers of cardiac dyssynchrony: an analysis from the Cardiac Resynchronization in Heart Failure (CARE-HF) study.
        Eur Heart J. 2009; 30: 2109-2116
        • Pitzalis M.V.
        • Iacoviello M.
        • Di Serio F.
        • et al.
        Prognostic value of brain natriuretic peptide in the management of patients receiving cardiac resynchronization therapy.
        Eur J Heart Fail. 2006; 8: 509-514
        • Hessel M.H.
        • Bleeker G.B.
        • Bax J.J.
        • Henneman M.M.
        • den Adel B.
        • Klok M.
        • Schalij M.J.
        • Atsma D.E.
        • van der Laarse A.
        Reverse ventricular remodelling after cardiac resynchronization therapy is associated with a reduction in serum tenascin-C and plasma matrix metalloproteinase-9 levels.
        Eur J Heart Fail. 2007; 9: 1058-1063
        • Tolosana J.M.
        • Mont L.
        • Sitges M.
        • et al.
        Plasma tissue inhibitor of matrix metalloproteinase-1 (TIMP-1): an independent predictor of poor response to cardiac resynchronization therapy.
        Eur J Heart Fail. 2010; 12: 492-498
        • Lellouche N.
        • De Diego C.
        • Cesario D.A.
        • Vaseghi M.
        • Horowitz B.N.
        • Mahajan A.
        • Wiener I.
        • Boyle N.G.
        • Fonarow G.C.
        • Shivkumar K.
        Usefulness of preimplantation B-type natriuretic peptide level for predicting response to cardiac resynchronization therapy.
        Am J Cardiol. 2007; 99: 242-246
        • Marfella R.
        • Di Filippo C.
        • Potenza N.
        • et al.
        Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: responders vs. non-responders.
        Eur J Heart Fail. 2013; 15: 1277-1288
        • Tarquini R.
        • Guerra C.T.
        • Porciani M.C.
        • Michelucci A.
        • Padeletti M.
        • Ricciardi G.
        • Chiostri M.
        • Jelic S.
        • Padeletti L.
        Effects of cardiac resynchronization therapy on systemic inflammation and neurohormonal pathways in heart failure.
        Cardiol J. 2009; 16: 545-552
        • Miller A.M.
        • Liew F.Y.
        The IL-33/ST2 pathway—a new therapeutic target in cardiovascular disease.
        Pharmacol Ther. 2011; 131: 179-186
        • Zile M.R.
        • Desantis S.M.
        • Baicu C.F.
        • Stroud R.E.
        • Thompson S.B.
        • McClure C.D.
        • Mehurg S.M.
        • Spinale F.G.
        Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure.
        Circ Heart Fail. 2011; 4: 246-256
        • Sundström J.
        • Evans J.C.
        • Benjamin E.J.
        • Levy D.
        • Larson M.G.
        • Sawyer D.B.
        • Siwik D.A.
        • Colucci W.S.
        • Wilson P.W.
        • Vasan R.S.
        Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart study.
        Eur Heart J. 2004; 25: 1509-1516